Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Recurrent Glioblastoma Multiforme Expressing PDGFR
NCT00171938Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2004
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in glioblastoma multiforme (GBM), sponsored by Novartis. Primary endpoint: Progression-Free Survival at 6 months. Started Apr 2004; status: terminated.
02
Drugs
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00171938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171938.